RecruitingPhase 1NCT06946225
ACTengine® IMA203 Combined With mRNA-4203
Studying Synovial sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immatics US, Inc.
- Intervention
- IMA203(biological)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (4)
- University of California San Francisco, San Francisco, California, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
ModernaTX, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06946225 on ClinicalTrials.govOther trials for Synovial sarcoma
Additional recruiting or active studies for the same condition.